1. Pink Sheet
  2. >>Legislation

Risks For Pharma Industry Remain As BIO Shifts Course On BIOSECURE Act

 
• By Sarah Karlin-Smith

Trade group’s break from WuXi Apptec allows BIO to reset its lobbying approach under its new CEO but doesn’t negate the business and supply chain disruptions that biopharma would feel from the proposed legislation.

picture of American and Chinese flags slightly overlapping.
• Source: Shutterstock

The Biotechnology Innovation Organization appeared to do a 180 degree turn on 13 March when its new President & CEO John Crowley announced the trade group’s support for the BIOSECURE Act, a bill that would make it harder for certain Chinese biotech companies to do business in the US. 

Key Takeaways

  • BIO’s shift in stance on BIOSECURE may be lobbying tactic to help secure changes to pending legislation, which continues to pose major threat for US biotech and pharma.

  • R&D, manufacturing and reimbursement complications could arise depending on how the legislation progresses and how guidance on any enacted law gets developed. Billions are at risk just with complications to WuXi’s business alone

Simultaneously, BIO announced that WuXi AppTec Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.